Howe & Rusling’s Novavax NVAX Stock Holding History

Howe & Rusling’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-50	Closed	-$9K	–	1003
2021 Q1	$9K	Sell	50 -50	-50%	-$9.96K	﹤0.01%	511
2020 Q4	$11K	Buy	100 +50	+100%	+$5.31K	﹤0.01%	480
2020 Q3	$5K	Buy	+50	New	+$6.09K	﹤0.01%	555

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Howe & Rusling's NVAX Position: Q2 2021 in Review

Howe & Rusling sold out of Novavax (NVAX) in Q2 2021, closing a stake of 50 shares — an estimated $9K sold.

Howe & Rusling first reported a position in NVAX in Q3 2020 and held it in 3 quarters. The position peaked at $11K in Q4 2020. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Howe & Rusling reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Howe & Rusling sold 50 Novavax shares in Q2 2021, an estimated $9K.
Howe & Rusling first reported a position in Novavax in Q3 2020 and held it in 3 quarters.
Howe & Rusling's Novavax position peaked at $11K in Q4 2020.
407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Howe & Rusling's 13F filing for Q2 2021, filed 13 Aug 2021.